Want to see IVA full AI Analyst Report?
IVA Stock Chart & Stats
$4.69
-$0.05(-1.11%)
At close: 4:00 PM EDT
$4.69
-$0.05(-1.11%)
Day’s Range― - ―
52-Week Range$2.82 - $7.98
Previous Close$4.46
Volume667.37K
Average Volume (3M)2.84M
Market Cap
$815.64M
Enterprise Value$920.42M
Total Cash (Recent Filing)$166.06M
Total Debt (Recent Filing)$66.63M
Price to Earnings (P/E)―
Beta0.39
Next Earnings
Mar 31, 2027EPS Estimate
-0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.54
Shares Outstanding237,986,700
10 Day Avg. Volume3,348,752
30 Day Avg. Volume2,842,401
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)-25.46
Price to Sales (P/S)164.91
P/FCF Ratio-7.30
Enterprise Value/Market Cap1.13
Enterprise Value/Revenue690.08
Enterprise Value/Gross Profit-2.86K
Enterprise Value/Ebitda-6.20
Forecast
1Y Price Target
$15.50Price Target Upside230.49% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-0.71
Revenue Forecast (FY)$3.90M
Bulls Say, Bears Say
Bulls Say
Late-Stage Clinical ProgressThe large, fully recruited NATiV3 trial has reached the final-patient milestone and remains scheduled for a late-2026 readout. This gives Inventiva a defined catalyst for resolving clinical uncertainty and supports potential regulatory preparation if efficacy is confirmed.
Phase II-B EfficacyPositive Phase II-B histological results provide clinical support for lanifibranor across important MASH endpoints, including fibrosis and disease resolution. These findings strengthen the rationale for the pivotal program and could support differentiation if replicated in Phase III.
Strengthened Financing PositionThe enlarged cash position and completed capital-structure actions provide funding visibility through the expected Phase III readout and potential NDA filing. That runway reduces near-term financing pressure and allows management to focus resources on clinical and regulatory execution.
Bears Say
Persistent Losses And Cash BurnInventiva remains dependent on external financing because operations generate substantial cash burn and revenue has deteriorated sharply. Continued losses constrain internal investment capacity, increase reliance on capital markets, and make financial execution important alongside clinical progress.
Negative Equity And Rising DebtNegative equity combined with materially higher debt weakens financial flexibility and increases the burden on future funding decisions. This capital structure may limit the company’s ability to absorb setbacks or finance development independently if milestones are delayed.
Tolerability RiskWeight gain, fluid retention, and hemoglobin decline remain meaningful tolerability considerations for lanifibranor. Even if attenuated versus full TZD agonists, these effects could influence prescribing, treatment persistence, and the commercial profile if they are confirmed in Phase III.
Inventiva News
IVA FAQ
What was Inventiva’s price range in the past 12 months?
Inventiva lowest stock price was $2.82 and its highest was $7.98 in the past 12 months.
What is Inventiva’s market cap?
Inventiva’s market cap is $815.64M.
When is Inventiva’s upcoming earnings report date?
Inventiva’s upcoming earnings report date is Mar 31, 2027 which is in 158 days.
How were Inventiva’s earnings last quarter?
Inventiva released its earnings results on Sep 28, 2026. The company reported -$0.201 earnings per share for the quarter, beating the consensus estimate of -$0.382 by $0.181.
Is Inventiva overvalued?
According to Wall Street analysts Inventiva’s price is currently Undervalued.
Does Inventiva pay dividends?
Inventiva does not currently pay dividends.
What is Inventiva’s EPS estimate?
Inventiva’s EPS estimate is -0.33.
How many shares outstanding does Inventiva have?
Inventiva has 237,986,700 shares outstanding.
What happened to Inventiva’s price movement after its last earnings report?
Inventiva reported an EPS of -$0.201 in its last earnings report, beating expectations of -$0.382. Following the earnings report the stock price went up 4.748%.
Which hedge fund is a major shareholder of Inventiva?
Currently, no hedge funds are holding shares in IVA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Inventiva Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.50 (230.49% Upside)
$15.50 (230.49% Upside)
Blogger Sentiment
Bullish
IVA Sentiment 100%
Sector Average 66%
Sector Average 66%
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.3%
Last 30 Days ▼ 0.4%
Last 30 Days ▼ 0.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-36.79%
12-Months-Change
Fundamentals
Return on Equity
-1625.48%
Trailing 12-Months
Asset Growth
37.06%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Inventiva
Inventiva S.A. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of orally administered small molecule therapeutics. The firm primarily targets serious conditions such as non-alcoholic steatohepatitis (NASH), various forms of mucopolysaccharidoses (MPS), and other significant diseases. The company's most advanced experimental drug is Lanifibranor, which has successfully completed Phase IIb clinical trials for the treatment of NASH. Inventiva is also progressing with Odiparcil, an asset that has finished its Phase IIa clinical studies for addressing the MPS VI subtype disease. Beyond these lead candidates, Inventiva maintains a robust pipeline of earlier-stage research and development programs, notably in oncology and other therapeutic areas. The company has also established important strategic alliances, including a partnership with AbbVie focused on treatments for autoimmune diseases, and a collaboration with Boehringer Ingelheim International GmbH aimed at discovering novel therapies for idiopathic pulmonary fibrosis. Inventiva S.A. was established in 2011 and is headquartered in Daix, France.
IVA Company Deck
IVA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was strongly focused on progress toward the NATiV3 phase III readout, positive phase II-B efficacy, preparation for potential regulatory and commercial milestones, and a strengthened financial position. Management also addressed known tolerability considerations, including weight gain, edema, and hemoglobin decline, while withholding additional blinded phase III safety and efficacy details. The positive development, financing, and preparation updates significantly outweighed the disclosed challenges and uncertainties.View all IVA earnings summariesIVA Stock 12 Month Forecast
Average Price Target
$15.50
▲(230.49% Upside)
Technical Analysis
Iovance Biotherapeutics
―
Kura Oncology
―
Urogen Pharma
―
Maravai Lifesciences Holdings
―
MBX Biosciences, Inc.
―
Ownership Overview
―
Insiders
0.82% Mutual Funds
1.55% Other Institutional Investors
97.47% Public Companies and
Individual Investors